GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GL...

Descripción completa

Detalles Bibliográficos
Autores principales: Nevola, Riccardo, Epifani, Raffaella, Imbriani, Simona, Tortorella, Giovanni, Aprea, Concetta, Galiero, Raffaele, Rinaldi, Luca, Marfella, Raffaele, Sasso, Ferdinando Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865319/
https://www.ncbi.nlm.nih.gov/pubmed/36675217
http://dx.doi.org/10.3390/ijms24021703
_version_ 1784875808005816320
author Nevola, Riccardo
Epifani, Raffaella
Imbriani, Simona
Tortorella, Giovanni
Aprea, Concetta
Galiero, Raffaele
Rinaldi, Luca
Marfella, Raffaele
Sasso, Ferdinando Carlo
author_facet Nevola, Riccardo
Epifani, Raffaella
Imbriani, Simona
Tortorella, Giovanni
Aprea, Concetta
Galiero, Raffaele
Rinaldi, Luca
Marfella, Raffaele
Sasso, Ferdinando Carlo
author_sort Nevola, Riccardo
collection PubMed
description To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.
format Online
Article
Text
id pubmed-9865319
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98653192023-01-22 GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives Nevola, Riccardo Epifani, Raffaella Imbriani, Simona Tortorella, Giovanni Aprea, Concetta Galiero, Raffaele Rinaldi, Luca Marfella, Raffaele Sasso, Ferdinando Carlo Int J Mol Sci Review To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios. MDPI 2023-01-15 /pmc/articles/PMC9865319/ /pubmed/36675217 http://dx.doi.org/10.3390/ijms24021703 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nevola, Riccardo
Epifani, Raffaella
Imbriani, Simona
Tortorella, Giovanni
Aprea, Concetta
Galiero, Raffaele
Rinaldi, Luca
Marfella, Raffaele
Sasso, Ferdinando Carlo
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
title GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
title_full GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
title_fullStr GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
title_full_unstemmed GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
title_short GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
title_sort glp-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865319/
https://www.ncbi.nlm.nih.gov/pubmed/36675217
http://dx.doi.org/10.3390/ijms24021703
work_keys_str_mv AT nevolariccardo glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT epifaniraffaella glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT imbrianisimona glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT tortorellagiovanni glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT apreaconcetta glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT galieroraffaele glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT rinaldiluca glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT marfellaraffaele glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives
AT sassoferdinandocarlo glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives

Ejemplares similares